Biotestx ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  9.9% 9.7% 7.7% 7.9% 12.7%  
Credit score (0-100)  26 27 31 29 18  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  30 36 0 0 0  
Gross profit  29.6 36.5 -6.8 -3.4 -4.6  
EBITDA  24.1 33.3 -6.8 -3.4 -4.6  
EBIT  24.1 33.3 -6.8 -3.4 -4.6  
Pre-tax profit (PTP)  24.1 33.3 -2.7 -21.6 -83.1  
Net earnings  24.1 33.3 -2.7 -21.6 -83.1  
Pre-tax profit without non-rec. items  24.1 33.3 -2.7 -21.6 -83.1  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  47.6 80.9 78.3 56.7 -26.4  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  56.1 92.6 96.7 78.5 3.8  

Net Debt  0.0 0.0 -0.0 -0.0 -3.8  
 
See the entire balance sheet

Volume 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  30 36 0 0 0  
Net sales growth  1,363.6% 23.3% -100.0% 0.0% 0.0%  
Gross profit  29.6 36.5 -6.8 -3.4 -4.6  
Gross profit growth  1,363.6% 23.3% 0.0% 50.3% -36.3%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  56 93 97 79 4  
Balance sheet change%  111.5% 65.0% 4.5% -18.8% -95.2%  
Added value  24.1 33.3 -6.8 -3.4 -4.6  
Added value %  81.4% 91.4% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  1.0 2.0 -1.0 0.0 0.0  
EBIT trend  1.0 2.0 -1.0 -2.0 -3.0  

Profitability 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  81.4% 91.4% 0.0% 0.0% 0.0%  
EBIT %  81.4% 91.4% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  81.4% 91.4% 100.0% 100.0% 100.0%  
Net Earnings %  81.4% 91.4% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  81.4% 91.4% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  81.4% 91.4% 0.0% 0.0% 0.0%  
ROA %  58.3% 44.9% -2.8% -24.6% -152.8%  
ROI %  67.7% 51.9% -3.3% -32.0% -293.1%  
ROE %  67.7% 51.9% -3.4% -32.0% -274.7%  

Solidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  84.8% 87.4% 80.9% 72.2% -87.4%  
Relative indebtedness %  28.7% 31.9% 0.0% 0.0% 0.0%  
Relative net indebtedness %  28.7% 31.9% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 0.0% 82.8%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  0.0 0.0 0.0 0.0 0.1  
Current Ratio  0.0 0.0 0.0 0.0 0.1  
Cash and cash equivalent  0.0 0.0 0.0 0.0 3.8  

Capital use efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -8.5 -11.6 -18.5 -21.8 -26.4  
Net working capital %  -28.7% -31.9% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -3 -5  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -3 -5  
EBIT / employee  0 0 0 -3 -5  
Net earnings / employee  0 0 0 -22 -83